ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,770.20
      0.55%
      US Tech 100
      19,636.04
      0.55%
      Dow Jones
      42,801.72
      0.52%
      Brent Oil
      70.235
      0.00%
      Bitcoin
      82,992.28
      -3.66%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Arbutus Biopharma Corporation (ABUS) Quote

      Arbutus Biopharma Corporation

      Arbutus Biopharma Corporation (ABUS)

      NASDAQ
      3.31
      -0.06
      (-1.78%)
      Closed March 09 4:00PM
      Delayed by 15 minutes
      3.31
      0.00
      (0.00%)
      After Hours: 7:39PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      3.31
      Bid
      3.22
      Ask
      3.50
      Volume
      1,175,835
      3.26 Day's Range 3.415
      2.30 52 Week Range 4.725
      Market Cap
      627.217M
      Previous Close
      3.37
      Open
      3.35
      Last Trade
      5
      @
      3.38
      Last Trade Time
      Financial Volume
      $ 3,901,418
      VWAP
      3.318
      Average Volume (3m)
      866,497
      Shares Outstanding
      189,491,685
      Dividend Yield
      -
      PE Ratio
      -8.61
      Earnings Per Share (EPS)
      -0.38
      Revenue
      18.14M
      Net Profit
      -72.85M

      About Arbutus Biopharma Corporation

      Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.tekmirapharm.com
      Headquarters
      Burnaby, British Columbia, Can
      Founded
      -
      Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was $3.37. Over the last year, Arbutus Biopharma shares have traded in a share price range of $ 2.30 to $ 4.725.

      Arbutus Biopharma currently has 189,491,685 shares outstanding. The market capitalization of Arbutus Biopharma is $638.59 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.61.

      Ask ADVFN Intelligence (AI)

      ABUS Latest News

      More News

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      March 07 2025
      ABUS (-1.78%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      March 06 2025
      ABUS (-1.78%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      March 06 2025
      ABUS (-1.78%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      March 06 2025
      ABUS (-1.78%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      March 06 2025
      ABUS (-1.78%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      March 03 2025
      ABUS (-1.78%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 25 2025
      ABUS (-1.78%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.06-1.780415430273.373.573.3111154423.4139438CS
      4-0.1-2.932551319653.413.73.2359590073.40376528CS
      12-0.23-6.497175141243.543.73.118664973.34596344CS
      26-1.27-27.72925764194.584.7253.119516293.68899181CS
      520.5821.24542124542.734.7252.310231113.46081102CS
      1560.4716.54929577462.844.7251.699395382.85051853CS
      2600.4716.54929577462.8490.8821429873.72244414CS

      ABUS - Frequently Asked Questions (FAQ)

      What is the current Arbutus Biopharma share price?
      The current share price of Arbutus Biopharma is $ 3.31
      How many Arbutus Biopharma shares are in issue?
      Arbutus Biopharma has 189,491,685 shares in issue
      What is the market cap of Arbutus Biopharma?
      The market capitalisation of Arbutus Biopharma is USD 638.59M
      What is the 1 year trading range for Arbutus Biopharma share price?
      Arbutus Biopharma has traded in the range of $ 2.30 to $ 4.725 during the past year
      What is the PE ratio of Arbutus Biopharma?
      The price to earnings ratio of Arbutus Biopharma is -8.61
      What is the cash to sales ratio of Arbutus Biopharma?
      The cash to sales ratio of Arbutus Biopharma is 34.59
      What is the reporting currency for Arbutus Biopharma?
      Arbutus Biopharma reports financial results in USD
      What is the latest annual turnover for Arbutus Biopharma?
      The latest annual turnover of Arbutus Biopharma is USD 18.14M
      What is the latest annual profit for Arbutus Biopharma?
      The latest annual profit of Arbutus Biopharma is USD -72.85M
      What is the registered address of Arbutus Biopharma?
      The registered address for Arbutus Biopharma is 100, 8900 GLENLYON PARKWAY, GLENLYON BUSINESS PARK, BURNABY, BRITISH COLUMBIA, V5J 5J8
      What is the Arbutus Biopharma website address?
      The website address for Arbutus Biopharma is www.tekmirapharm.com
      Which industry sector does Arbutus Biopharma operate in?
      Arbutus Biopharma operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CAPSCapstone Holding Corp
      $ 3.50
      (1,300.00%)
      		36.33k
      ABLVAble View Global Inc
      $ 1.73
      (137.18%)
      		5.13M
      SUNESUNation Energy Inc
      $ 0.402999
      (127.55%)
      		476.73M
      BTOGBit Origin Ltd
      $ 0.6117
      (118.46%)
      		618.03M
      DWTXDogwood Therapeutics Inc
      $ 6.63
      (49.66%)
      		25.77M
      ALBTAvalon GloboCare Corporation
      $ 6.96
      (-36.15%)
      		577.55k
      SCNXScienture Holdings Inc
      $ 1.55
      (-35.68%)
      		1.59M
      ACXPAcurx Pharmaceuticals Inc
      $ 0.4572
      (-29.88%)
      		1.18M
      RETOReTo Eco Solutions Inc
      $ 5.42
      (-27.73%)
      		108.27k
      OCTOEightco Holdings Inc
      $ 1.08
      (-27.03%)
      		336.99k
      BTOGBit Origin Ltd
      $ 0.6117
      (118.46%)
      		622.67M
      SUNESUNation Energy Inc
      $ 0.402999
      (127.55%)
      		482.05M
      NVDANVIDIA Corporation
      $ 112.69
      (1.92%)
      		341.94M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 10.675
      (-0.70%)
      		143.04M
      ICONIcon Energy Corporation
      $ 0.169898
      (17.17%)
      		142.23M

      ABUS Discussion

      View Posts
      db7 db7 6 days ago
      https://www.globenewswire.com/news-release/2025/03/03/3035733/14025/en/Genevant-Sciences-and-Arbutus-Biopharma-Initiate-International-Patent-Infringement-Enforcement-Actions-Against-Moderna.html
      👍️0
      db7 db7 1 week ago
      some scenarios(imo?):

      BEST case scenario: A letter of intent to completely divest of the HBV assets 'prior' to Pfizer Markman ruling for a respectectable amount; this would put a solid floor at the purchase price and leave risk-free upside into Pfizer Markman result. HUGE cherry on top if result leaned heavily our way. This 'could be' a scenario where we see $15+ ??

      WORST case scenario: Pfizer Markman comes out prior to HBV deal and leans towards Pfizer. Maybe temporarily drops share price to $2.50 to $2.75(?) Then we seem to be weak and lose some of our HBV bargaining power(?)


      Timing?

      HBV:
      Based on commentary when the new directors were announced, 'possibly' hear about an HBV transaction prior to the annual general meeting in mid-March(?)
      .. BUT obviously could drag out.... 'should be' this year????

      Pfizer Markman ruling:
      Supposedly 1st half 2025 but in looking at the Judge's past Markman rulings it could be ~8 months'ish???

      Moderna Summary Judgement in regards to Gov't contracts..etc:
      Q2/Q3 if i recall correctly

      Moderna Hearing:
      Sept 2025

      Qilu payment:
      1st half 2025



      Would LOVE to have a bunch of solid wins in 1st half 2025....
      👍️0
      db7 db7 1 week ago
      tell me about it!?! ... and of course i keep rolling calls on her............. someday?!? 'i think' this will at minimum double this year with max downside to around $2.50ish 'if' they completely lost on pfizer markman(?)
      👍️0
      MWM MWM 2 weeks ago
      long wait on this one. Maybe some day!
      👍️ 1
      db7 db7 2 weeks ago
      "The Company will temporarily pause participation in investor meetings and conferences while the new board and management team reviews development plans and strategic options for its hepatitis B programs."
      👍️0
      db7 db7 2 weeks ago
      https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-changes-board-directors-and-appointment
      👍️0
      db7 db7 2 weeks ago
      Whitefort message and adding: https://www.sec.gov/Archives/edgar/data/1447028/000092189525000560/xslSCHEDULE_13D_X01/primary_doc.xml
      👍️0
      db7 db7 3 weeks ago
      ROIV filed sc-13d yesterday: "Roivant and its representatives are evaluating potential near-term changes to the composition of the board of directors and management of the Issuer. Roivant's representatives may also be engaged in discussions related to such potential changes in the board of directors and management of the Issuer with other shareholders of the Issuer. "
      👍️0
      Monksdream Monksdream 3 weeks ago
      ABUS under $4

      👍️0
      MWM MWM 2 months ago
      ABUS made it on mad money tonight, the ultimate spec! 

      https://www.cnbc.com/2025/01/13/cramers-lightning-round-arbutus-biopharma-is-the-ultimate-spec.html
      👍️ 1
      MWM MWM 2 months ago
      I'll look now 👍🏽
      👍️0
      db7 db7 2 months ago
      MWM see today’s update. Qilu milestones coming and no more atm

      Pfizer Markman results ‘soon’. Assuming they are positive we should have liftoff. ATM program killed the Moderna Markman last year and won’t be used during Pfizer results it sounds like

      Now to just get a decisive victory!?!???
      👍️0
      db7 db7 4 months ago
      nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944
      👍️0
      db7 db7 4 months ago
      2 days to AASLD...
      👍️0
      mick mick 5 months ago
      👍️0
      db7 db7 5 months ago
      2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data
      👍️0
      mick mick 6 months ago
      https://www.stockscores.com/charts/charts/?ticker=ABUS
      👍️0
      mick mick 6 months ago
      ABUS
      Arbutus Biopharma Corporation
      4.5488
      0.0388 (0.86%)
      Volume: 1,579,948
      Day Range: 4.39 - 4.56
      Last Trade Time: 7:46:00 PM EDT
      👍️0
      db7 db7 6 months ago
      breaking out; dare i say 'someone' knows 'something'(?)
      👍️0
      db7 db7 6 months ago
      ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"
      👍️0
      db7 db7 6 months ago
      ABUS over $4
      👍️0
      Monksdream Monksdream 6 months ago
      ABUS under $4
      👍️0
      DewDiligence DewDiligence 7 months ago
      ABUS pares pipeline–reduces workforce 40%:

      https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

      The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

      Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.
      👍️0
      Rockurstocks Rockurstocks 8 months ago
      Not for long! $ABUS$
      👍️0
      Monksdream Monksdream 8 months ago
      ABUS under $4
      👍️0
      mick mick 8 months ago
      ABUS
      Arbutus Biopharma Corporation
      3.645
      -0.135 (-3.57%)
      Volume: 449,700
      Day Range: 3.645 - 3.845
      Last Trade Time: 2:29:04 PM EDT
      👍️0
      Monksdream Monksdream 8 months ago
      ABUS new 52/week high
      👍️0
      db7 db7 8 months ago
      👍️0
      db7 db7 9 months ago
      https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt
      👍️0
      db7 db7 9 months ago
      New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852
      👍️0
      db7 db7 9 months ago
      Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf
      👍️0
      mick mick 9 months ago
      ABUS
      Arbutus Biopharma Corporation
      3.341
      -0.019 (-0.57%)
      Volume: 534,638
      Day Range: 3.30 - 3.385
      Last Trade Time: 12:14:00 PM EDT
      Delayed by 15 minutes
      👍️0
      db7 db7 10 months ago
      EASL June 6-8th:
      https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

      "
      HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
      "
      👍️0
      db7 db7 10 months ago
      Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
      https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

      other important events of late include:

      1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

      2) the Markman order against Moderna that went in their favor:
      https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

      3) Activist becoming involved:
      https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value
      👍️0
      db7 db7 10 months ago
      issue here, now, might be too many open $3 calls? will mm's hold her under....
      👍️0
      db7 db7 10 months ago
      mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price
      👍️0
      MWM MWM 10 months ago
      Nice!
      👍️0
      db7 db7 10 months ago
      https://www.businesswire.com/news/home/20240517970994/en/
      👍️0
      db7 db7 10 months ago
      from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."
      👍️0
      Monksdream Monksdream 10 months ago
      ABUS under $3
      👍️0
      mick mick 11 months ago
      TWTR
      Twitter Inc
      53.70
      0.00 (0.00%)
      Volume:
      👍️0
      Monksdream Monksdream 11 months ago
      ABUS new 52 hi
      👍️0
      db7 db7 11 months ago
      looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

      also, looking forward to EASL in june
      👍️0
      mick mick 11 months ago
      ABUS
      Arbutus Biopharma Corporation
      3.00
      0.08 (2.74%)
      Volume: 1,253,240
      Day Range: 2.86 - 3.11
      Bid: 2.99
      Ask: 3.00
      Last Trade Time: 9:56:51 AM EDT
      Total Trades: 3,890
      👍️0
      mick mick 11 months ago
      ABUS
      Arbutus Biopharma Corporation
      3.00
      0.08 (2.74%)
      Volume: 1,253,240
      Day Range: 2.86 - 3.11
      Bid: 2.99
      Ask: 3.00
      Last Trade Time: 9:56:51 AM EDT
      Total Trades: 3,890
      👍️0
      mick mick 11 months ago
      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      03/05/2024 04:48:49 PM
      👍️0
      mick mick 11 months ago
      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      03/05/2024 04:48:49 PM
      👍️0
      mick mick 11 months ago
      Arbutus to Participate in Two Upcoming Investor Conferences
      03/08/2024 07:30:00 AM
      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      03/05/2024 04:48:49 PM
      👍️0
      mick mick 11 months ago
      Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
      04/04/2024 08:30:49 AM
      Arbutus to Participate in Two Upcoming Investor Conferences
      03/08/2024 07:30:00 AM
      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      03/05/2024 04:48:49 PM
      👍️0
      Paullee Paullee 11 months ago
      07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

      US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

      Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

      Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
      👍️0

      Your Recent History

      NASDAQ
      ABUS
      Arbutus Biopharma
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads